Novo says Wegovy lowers BMI in children in trial
Novo Nordisk said Wegovy lowered BMI and obesity rates in children in a trial.
Why it matters: Possible first drug for under-12s.
Sources: CNBC · See it on the globe
The story so far · 2 days, November 16 to 17, 2026
One Turn followed this story across 2 editions, from Copenhagen, Denmark on November 16, 2026. Newest first.
Approved from age 12.
Open the latest on the 3D globe →
Novo Nordisk said Wegovy lowered BMI and obesity rates in children in a trial.
Why it matters: Possible first drug for under-12s.
Sources: CNBC · See it on the globe
Novo Nordisk said Wegovy lowered BMI and obesity rates in children in a trial. No drug is approved for children under 12.
Why it matters: Younger children may gain a treatment option.
Sources: CNBC · See it on the globe